April Breyer Menon, Author at Venable's BiologicsHQ

PTAB Denies Institution of Two Elevidys® Gene Therapy IPRs

by April Breyer Menon | May 18, 2026

On May 15, 2026, the Director of the U.S. Patent and Trademark Office issued summary institution decisions denying institution on the merits of two additional inter partes review (“IPR”) proceedings, IPR2026-00167 and IPR2026-00168, filed by Sarepta Therapeutics, Inc....

Accord’s Immgolis™ / Immgolis Intri™ (golimumab-sldi) Approved as First Simponi® / Simponi Aria® (golimumab) Interchangeable Biosimilars

by April Breyer Menon | May 18, 2026

On May 15, 2026, the FDA approved the first biosimilars of Janssen’s Simponi® / Simponi Aria® (golimumab), Accord and Bio-Thera’s Immgolis™ / Immgolis Intri™ (golimumab-sldi). Both biosimilars were approved with skinny labels. Immgolis™ is...

PTAB Denies Institution of One Elevidys® IPR and Institutes Another

by April Breyer Menon | May 8, 2026

On May 6, 2026, the Director of the U.S. Patent and Trademark Office issued bulk order institution decisions in two inter partes review (“IPR”) proceedings filed by Sarepta Therapeutics, Inc. against Genzyme relating to patents associated with gene therapy products,...

FDA Approves Interchangeable Insulin Glargine Biosimilar Langlara™ (insulin glargine-aldy)

by April Breyer Menon | May 7, 2026

On April 29, 2026, the U.S. Food and Drug Administration (FDA) approved Sunshine Lake Pharma’s Langlara™ (insulin glargine-aldy) biosimilar to Sanofi’s Lantus® (insulin glargine), for the treatment of adult and pediatric patients with type 1 diabetes and adults...

Federal Circuit Reverses JMOL of Invalidity of Teva’s Ajovy® Patents

by April Breyer Menon | Apr 20, 2026

On April 16, 2026, the U.S. Court of Appeals for the Federal Circuit reversed the district court’s judgment as a matter of law (“JMOL”) finding Teva’s asserted patent claims invalid for lack of written description and enablement in Teva Pharmaceuticals v. Eli Lilly...

« Older Entries

Next Entries »

Methodology

Information contained in the Venable BiologicsHQ database relates to FDA-approved drug products listed in the CDER Purple Book or on the FDA website (www.fda.gov). Information relating to FDA licensed products, FDA-approved indications, and aBLA and 505(b)(2) applications is obtained from public sources including the U.S. FDA website (www.fda.gov). Information relating to litigations is given only for cases active from January 31, 2010 onward. Information relating to foreign biosimilar / biologics follow-on products approved in Australia, Canada, the E.U., Japan and South Korea is from public sources. Statistics graphics are compiled from information contained in the Venable BiologicsHQ database.

Disclaimer

The individuals who maintain this site work for Venable LLP. The information, comments and links posted on this site do not constitute legal advice. No attorney-client relationship has been or will be formed by any communication(s) to, from or with the site and/or the author. For legal advice, contact an attorney at Venable LLP or an attorney actively practicing in your jurisdiction. Do not send any confidential or privileged information to the author; neither Venable LLP nor the author will assume any liability or responsibility for it. If you send any information, documents or materials to the site, you give permission for the author to include them on or in the site. No information, documents or materials you send to the site will be considered confidential or privileged by Venable LLP or its lawyers. Also, no such information, documents or materials will be returned to you. All decisions relating to the content belong to the author.